We spoke to Dr Benedikt Schrage (Karolinska Institute, Stockholm, Sweden) for the key findings from his prospective study examining the association between the use of implantable cardioverter defibrillators and mortality in patients with heart failure. He also discusses how physicians might incorporate these findings into routine practice.
Speaker’s Disclosures: Benedikt Schrage has received funding from the German Research Foundation and received speaker’s fees from AstraZeneca.
1. What were the key findings from your prospective study that examined the association between implantable cardioverter-defibrillator use and mortality in patients with heart failure? (0:05)
2. How should physicians incorporate these observations into routine practice when considering implantable devices for their patients with heart failure? (1:20)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Society of Cardiology (ESC) Congress 2019 in Paris, France, September 2019.
Share this Video
Related Videos In Heart Failure
Anthony Tang, ACC 2021: Findings from the RAFT-AF Trial
It was a great pleasure to meet with Anthony Tang to discuss the RAFT-AF trial results investigating the safety and efficacy of catheter ablation-based rhythm control compared with rate control for the treatment of patients with atrial fibrillation and heart failure, presented at ACC 2021. Abstract Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus […]
Michiel Rienstra and Bao-Oanh Nguyen, EHRA 2021 – Long-term Outcomes of the RACE 3 Trial
Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate […]
Hugh Calkins, AF Symposium 2021: Atrial Fibrillation and HFrEF and HFpEF
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about atrial fibrillation and heart failure with reduced and preserved ejection fraction. Questions: What is the prevalence of atrial fibrillation (AF) in patients with heart failure (HF) and reduced (HFrEF) and preserved (HFpEF) ejection fraction? (0.13) What is the impact of AF on […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!